利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11575 条记录 (耗时 0.037 秒)

    Method for Treating Inflammatory Skin Conditions and other Topical Conditions or Disorders
    41.
    发明公开
    Method for Treating Inflammatory Skin Conditions and other Topical Conditions or Disorders 审中-公开

    公开(公告)号：US20240180837A1

    公开(公告)日：2024-06-06

    申请号：US18531539

    申请日：2023-12-06

    申请人： Marc Selner

    发明人： Marc Selner

    IPC分类号： A61K9/127 ,  A61K9/00 ,  A61K45/06 ,  A61K47/10

    CPC分类号： A61K9/1277 ,  A61K9/0014 ,  A61K45/06 ,  A61K47/10

    摘要： The present invention is directed to transdermal drug delivery composition designed for the effective administration of a pharmacological agent having a formulation utilizing specially formulated ethosomes or transferosomes, enabling penetration of both the stratum corneum and dermis layers of the skin. The ethosomes, characterized by their non-polar and fat-soluble nature, incorporate isopropyl alcohol or ethanol as the alcohol component. Introducing lipid-based vesicles with remarkable proficiency in encapsulating medications and immunosuppressants. This unique composition significantly enhances the penetration of the stratum corneum layer. This ensures precise delivery to affected areas upon topical application. By transcending the limitations of conventional treatments, the disclosed method holds substantial promise for advancing therapeutic outcomes and elevating the overall patient experience.

    LIPID NANOPARTICLE WITH TARGET INTEGRIN FUNCTION AND USES THEREOF
    48.
    发明公开
    LIPID NANOPARTICLE WITH TARGET INTEGRIN FUNCTION AND USES THEREOF 审中-公开

    公开(公告)号：US20240139113A1

    公开(公告)日：2024-05-02

    申请号：US17975968

    申请日：2022-10-28

    申请人： Hung-Yun Lin

    发明人： Hung-Yun Lin

    IPC分类号： A61K9/51 ,  A61K9/00 ,  A61K9/127 ,  A61K31/704 ,  A61K47/28

    CPC分类号： A61K9/5123 ,  A61K9/0019 ,  A61K9/1271 ,  A61K31/704 ,  A61K47/28

    摘要： The present disclosure provides a lipid nanoparticle and uses of the lipid nanoparticle for treating cancer, targeting integrin αvβ3, anti-angiogenesis to prevent cancer metastasis and reducing the cytotoxicity of anti-cancer drugs to normal cells. In addition, since it can inhibit angiogenesis, it also can be used in vascular related diseases. The lipid nanoparticle provides targeting cell surface integrin αvβ3, the nano-liposome specific against digestion system-related cancers locally and systemically. The lipid nanoparticle of the present disclosure would target cancer cells instead of normal cells. Even normal cells contain integrin αvβ3, however, the lipid nanoparticle of the present disclosure only recognizes the conformation of integrin αvβ3 on the cancer cells. The lipid nanoparticle of the present disclosure can equip with other targeting molecules, payload with other anti-cancer drugs, and can combine with radiation therapy and reduce radiation therapeutic threshold.

    IPA-3-loaded liposomes and methods of use thereof
    49.
    发明授权
    IPA-3-loaded liposomes and methods of use thereof 有权

    公开(公告)号：US11969396B2

    公开(公告)日：2024-04-30

    申请号：US18047915

    申请日：2022-10-19

    申请人： University of Georgia Research Foundation, Inc.

    发明人： Somanath Rammohan Shenoy ,  Brian S. Cummings ,  Wided Najahi-Missaoui

    IPC分类号： A61K31/105 ,  A61K9/127 ,  A61P35/00

    CPC分类号： A61K31/105 ,  A61K9/1271 ,  A61K9/1275 ,  A61P35/00

    摘要： Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof. Methods of use, for example methods of treating cancer, particularly prostate and breast cancer by administering the composition to subjects in need thereof, are also provided.